Ensign Peak Advisors, Inc Ascendis Pharma A/S Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 2,223 shares of ASND stock, worth $323,735. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,223
Previous 2,983
25.48%
Holding current value
$323,735
Previous $445,000
31.24%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
60.2MCall Options Held
80.3KPut Options Held
216K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.47 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$805 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$743 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$648 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$638 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.13B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...